ReviewVaccine2019
Vaccines for maternal immunization against Group B Streptococcus disease: WHO perspectives on case ascertainment and case definitions.
Review in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Clinical and Epidemiological Landscape of Antimicrobial Resistance and Virulence inAntibiotics (Basel, Switzerland) · 2026Review
- Temporal trends in Group B Streptococcus colonization, serotype distribution, and antimicrobial resistance among pregnant women in the Brazilian Amazon across the COVID-19 pandemic, 2018-2023.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- A large prospective study of group B Streptococcus carriage in pregnant women in Morocco: prevalence, serotype distribution, antimicrobial resistance and virulence determinants.BMC infectious diseases · 2025Article
- CRISPR typing and phage content of colonizing Group BFrontiers in cellular and infection microbiology · 2025Article
- Surface protein distribution in Group B Streptococcus isolates from South Africa and identifying vaccine targets through in silico analysis.Scientific reports · 2024Article
- Molecular Epidemiology of Group B Streptococcus Colonization in Egyptian Women.Microorganisms · 2022Article
- Alterations of the vaginal microbiome in healthy pregnant women positive for group B Streptococcus colonization during the third trimester.BMC microbiology · 2022Article
- A group BCell reports. Medicine · 2022Article
- Alterations of the Human Lung and Gut Microbiomes in Non-Small Cell Lung Carcinomas and Distant Metastasis.Microbiology spectrum · 2021Article
- Group B Streptococcal Colonization in African Countries: Prevalence, Capsular Serotypes, and Molecular Sequence Types.Pathogens (Basel, Switzerland) · 2021Review
- Estimation of country-level incidence of early-onset invasive Group B Streptococcus disease in infants using Bayesian methods.PLoS computational biology · 2021Article
- Vaccines to Prevent Meningitis: Historical Perspectives and Future Directions.Microorganisms · 2021Review
- Article
- Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible?Frontiers in immunology · 2020Review
- Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement.Frontiers in immunology · 2020Review
- Neonatal intestinal colonization ofGut microbesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 9 institutions in 8 countries.
Funding
Abstract
Group B Streptococcus (GBS) is an important cause of disease in young infants, stillbirths, pregnant and post-partum women. GBS vaccines for maternal immunization are in development aiming to reduce this burden. Standardisation of case definitions and ascertainment methodologies for GBS disease is needed to support future trials of maternal GBS vaccines. Considerations presented here may also serve to promote consistency in observational studies and surveillance, to better establish disease burden. The World Health Organization convened a working group to provide consensus guidance for case ascertainment and case definitions of GBS disease in stillbirths, infants, pregnant and post-partum women, with feedback sought from external stakeholders. In intervention studies, case capture and case ascertainment for GBS disease should be based on antenatal recruitment of women, with active follow-up, systematic clinical assessment, standardised sampling strategies and optimised laboratory methods. Confirmed cases of invasive GBS disease in stillbirths or infants should be included in a primary composite endpoint for vaccine efficacy studies, with GBS cultured from a usually sterile body site (may be post-mortem). For additional endpoints, or observational studies, confirmed cases of GBS sepsis in pregnant and post-partum women should be assessed. Culture independent diagnostic tests (CIDTs) may detect additional presumed cases, however, the use of these diagnostics needs further evaluation. Efficacy of vaccination against maternal and neonatal GBS colonisation, and maternal GBS urinary tract infection could be included as additional, separate, endpoints and/or in observational studies. Whilst the focus here is on specific GBS disease outcomes, intervention studies also present an opportunity to establish the contribution of GBS across adverse perinatal outcomes, including all-cause stillbirth, preterm birth and neonatal encephalopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.